ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 41 | October 25, 1985

Download PDF Visit The Full Archive

Related Articles

Hudis’s Address At ASCO 2014: On Value & Commitment

June 6, 2014

BCTF July, Sept. Meetings To Develop New Research Ideas

December 3, 1976

Blacks, Whites Have Same Contralateral Breast Cancer Risk While On Tamoxifen

December 31, 2004

Carcinogenesis Program Direction Changes Near for Extramural research; Workshop Topics Listed

April 22, 1977

Obesity At Prostate-Cancer Diagnosis Increases Risk

March 30, 2007

Advisors Approve Lung Screening Trial Testing Spiral CT Vs. X-Ray, For $200M.

November 23, 2001